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The NS3 proteinase of hepatitis C virus utilizes NS4A as a cofactor for cleavages at four sites (3/4A, 4A/4B, 4B/5A, and
5A/5B) in the nonstructural region of the viral polyprotein. To characterize NS4A for its role in modulating the NS3 proteinase
activity at various cleavage sites, synthetic peptides spanning various parts of NS4A were synthesized and tested in a cell-
free trans-cleavage reaction using purified NS3 proteinase domain and polyprotein substrates. The NS3 proteinase domain
was expressed in Escherichia coli, purified, denatured, and refolded to an enzymatically active form. We found that a 12-
amino-acid peptide containing amino acid residues 22 to 33 in NS4A (CVVIVGRIVLSG) was sufficient for cofactor activity
in NS3-mediated proteolysis. The peptide enhanced the cleavage at the NS5A/5B site and was necessary for NS3-mediated
cleavage at NS4A/4B and NS4B/5A. Sequential amino acid substitution within the designated peptide identified residues
I29 and I25 as critical for potential cofactor activity. We provide evidence that the NS4A peptide and the NS3 catalytic domain
form an enzymatically active complex. These data suggest that the central 12-amino-acid peptide (aa 22–33) of NS4A is
primarily important for the cofactor activity through complex formation with NS3, and the interaction may represent a new
target for antiviral drug development. q 1996 Academic Press, Inc.
INTRODUCTION tein is proteolytically processed by two virally encoded
proteinases, NS2-3 and NS3, to produce mature proteins
Hepatitis C virus (HCV), the major etiological agent of
NS2 through NS5B. The cleavage between NS2 and NS3
posttransfusion non-A non-B hepatitis (Choo et al., 1989;
is accomplished intramolecularly by a poorly character-
Kuo et al., 1989), is classified as a member of the flavi-
ized viral metalloproteinase encoded within NS2 and the
virus family (Miller and Purcell, 1990). Several genotypes
NS3 proteinase domain (Hijikata et al., 1993; Grakoui et
of HCV, each with many strains, have been identified
al., 1993c; Reed et al., 1995). NS3 proteinase mediates
(Simmonds et al., 1993). HCV contains a positive-sense
the rest of the cleavages in the nonstructural part of
linear RNA genome of approximately 9.5 kb which en-
the polyprotein, with processing between NS3 and NS4A
codes a single large polyprotein precursor (Choo et al.,
occurring in cis, and cleavages between 4A/4B, 4B/5A,
1991; Takamizawa et al., 1991). Although it is yet to be
and 5A/5B occurring in trans. This proteinase activity has
confirmed by infectivity assay, cell-free translation of the
been mapped to the amino-terminal 181 aa residues of
viral RNA (Hijikata et al., 1991) and cell culture expres-
NS3. It is a member of the serine proteinase family and
sion studies (Grakoui et al., 1993a,b; Hijikata et al., 1993)
contains serine, histidine, and aspartic acid as a catalytic
have established that the HCV polyprotein is proteolyti-
triad, serine being the active site residue (Grakoui et al.,
cally processed by host and viral proteinases into 10
1993b; Tomei et al., 1993). It has been shown that NS4A
different proteins which are encoded as follows: NH2-C- enhances the cleavage at the 5A/5B site and is abso-
E1-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-NS5B-COOH. The
lutely required for cleavage at the 4B/5A site (Failla et
proteins encoded within the amino-terminal one-third, C,
al., 1994; Lin et al., 1995). NS4A is cleaved off from NS3
E1, E2, and p7, have been reported to be proteolytically
by intramolecular cleavage at NS3/4A site and has been
processed into mature forms by host signalases (Hijikata
shown to enhance NS3 activity in cis and in trans (Failla
et al., 1991; Lin et al., 1994). The remainder of the polypro-
et al., 1994). It is a 54-amino-acid residue protein and
the central region has been reported to be important for
1 To whom correspondence and reprint requests should be ad- the cofactor activity (Lin et al., 1995). In addition to its
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role in modulating NS3-mediated proteolysis, NS4A hasResearch Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey
also been reported to enhance phosphorylation of NS5A07033. Fax: (908) 298-3918; E-mail: bimalendu.dasmahapatra@spcorp.
com. (Tanji et al., 1995). NS4A is a multifunctional protein and
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the mechanisms by which it enhances NS3 proteinase erichia coli expression, purification, and refolding of the
His-HIV-HCV proteinase domain will be described else-activity and phosphorylation of NS5A are not known.
Understanding the precise mechanism of NS4A in where (Ramanathan et al., 1996).
To produce HCV NS3 substrate polypeptides with dif-modulating NS3 activity is important, not only for physical
and biochemical characterization of the enzyme, but also ferent cleavage sites, DNA fragments from the plasmid
pBRTM/HCV encoding regions of nonstructural polypro-for the design of specific inhibitors which might be devel-
oped as potential antiviral drugs. In this report, we exam- tein were isolated and cloned into the cell-free expres-
sion plasmid pBD7 (DasMahapatra, 1993). The HCV cod-ine the nature of the NS4A cofactor activity in a biochemi-
cal trans-cleavage reaction using purified NS3 protein- ing sequences in these plasmids are in frame with the
initiator ATG of pBD7. The plasmid pAH 21 contains HCVase, NS4A synthetic peptides, and in vitro-translated
polypeptides as substrates. We have identified a 12-aa sequences from 9474 through 13,610; the plasmid
pNBNae contains nucleotides 9604 to 10,238. Similarlyresidue NS4A-specific synthetic peptide (aa 22–33) as
the minimum sequence necessary to modulate the NS3- the plasmids pJB1003 and pTS102 contain HCV se-
quences from 9798 to 13,606 and from nucleotidesmediated proteolytic activity and have found by alanine
substitution that the hydrophobic amino acids in the pep- 11,462 to 13,190, respectively. Nucleotide numbers corre-
spond to the numbers in the plasmid pBRTM/HCV 1-tide are important for the cofactor activity. We show that
the same peptide of NS4A increases the efficiency of 3001 (Grakoui et al., 1993a). Restriction enzymes were
purchased from New England Biolabs, Inc. DNA manipu-cleavage at the 5A/5B site and is absolutely required by
the NS3 proteinase for the cleavages at the 4A/4B and lations and other recombinant techniques were per-
formed according to the Molecular Cloning Manual (Sam-4B/5A sites. We demonstrate for the first time that the
peptide forms an enzymatically active complex with the brook et al., 1989).
NS3 proteinase domain.
Cell-free transcription and translation
MATERIALS AND METHODS The plasmid DNAs encoding HCV polypeptides with
cleavage sites were linearized with appropriate restric-Construction of plasmid DNAs for expression of the
tion enzymes prior to transcription with T7 RNA polymer-NS3 proteinase domain and polypeptide substrates
ase. The plasmid pAH21 was linearized with Bsu36I and
The plasmid pBRTM/HCV 1-3011 was used as the transcribed (DasMahapatra, 1993) to produce RNA en-
starting material and the nucleotide numbers indicated coding HCV polyprotein (NS3*-4A-4B*) from amino acid
refer to the HCV sequence in the plasmid pBRTM/HCV residue 1650 through amino acid residue 1956. Similarly,
1-3011 (Grakoui et al., 1993a). A DNA fragment from nu- the transcript derived from the EcoRI-linearized plasmid
cleotide 7607 to 8344, encoding the amino-terminal 246 pNBNae encodes the HCV protein (NS4A*-4B*) from aa
amino acids of NS3, was isolated after several subclon- residue 1693 to 1903. The RNA produced from the plas-
ing procedures and was cloned into AspI-digested, mid pJB1003 after linearizing with AvrII encodes HCV
Klenow polymerase-treated pQE30 (HIV) (B. DasMahapa- protein (NS4B*-5A*) from aa 1757 to 2048, and the RNA
tra, personal communication) to produce the plasmid transcribed from the EcoRI-linearized plasmid pTS102
pBJ1015. A translational stop codon after amino acid 183 codes for HCV protein (NS5A*-5B*) from aa 2312 to 2621.
in the NS3 sequence in plasmid pBJ1015 was engineered The in vitro-transcribed RNAs were translated in rabbit
by inserting the oligonucleotide reticulocyte lysates (Promega) in presence of [35S]methi-
onine (Amersham) at 307 for 1 hr according to the suppli-GA TCA CCG GTC TAG ATC T
er’s recommendation. Translation reaction were termi-
T GGC CAG ATC TAG A nated by adding DNase-free RNase (Boehringer Mann-
heim) and cycloheximide (Sigma) to 10 mg/ml, followed
after nucleotide 8144 in the HCV genome. The resulting
by incubation for 15 min at 307.
plasmid, His-HIV-NS3(183), expresses a fusion protein
containing a polyhistidine (61 His) tag for purification, Cell-free proteinase assay
an 11-aa peptide containing the HIV-1 protease cleavage
site to remove the purification tag if necessary, and the Standard proteinase assays were initiated by the addi-
tion of 1 mM refolded proteinase to 2 ml 35S-labeled trans-amino-terminal 183 aa of NS3. The construction was veri-
fied by nucleotide sequencing. The bacterially expressed lated substrate in a 20-ml reaction volume containing 10
mM Tris, pH 7.5, 175 mM NaCl, 7.5 mM DTT, 0.5% EDTA,NS3 catalytic domain was purified from inclusion bodies,
denatured with 6 M guanidine–HCl, and refolded into 0.1% Tween 20, and 12% glycerol, followed by incubation
at 307 for 1 hr. NS4A-specific peptides were added toenzymatically active form with detergent. The preparation
was greater than 95% pure. The amino-terminal 15 aa the standard assay mixture prior to the incubation, and
appropriate solvents were added to standard assay mix-residues of the fusion protein were confirmed by amino
acid sequence determination. Detailed methods of Esch- tures as controls. Cleavage reactions were terminated
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by adding an equal volume of 21 Laemmli sample
buffer and boiling for 3 min. Cleavage products were
analyzed by SDS – 15% PAGE (Laemmli, 1970) and au-
toradiography.
Peptide synthesis
The peptides containing NS4A sequence and its deriv-
atives were synthesized using Fmoc chemistry on an ABI
Model 431 A peptide synthesizer. The peptides were
FIG. 1. Schematic representation of HCV genome and polyprotein.
cleaved off the resin and deprotected following a stan- HCV NS3 proteinase catalytic domain used in the experiments is shown
dard TFA cleavage protocol. The peptides were purified as a hatched box. The polyprotein regions used as in vitro-translated
substrates are shown as solid black bars. Vertical lines indicate cleav-on reverse-phase HPLC and confirmed by mass spectro-
age site positions relative to the precursor polyprotein.metric analysis.
Complex formation between the NS4A peptide and
presence or absence of the NS4A peptide. The results ofpurified His-NS3 proteinase
the cell-free trans-cleavage reactions are shown in Fig.
To study complex formation between the peptide and 2. The polypeptide containing the 3/4A and 4A/4B sites
the proteinase, the 13-aa synthetic peptide (aa 22–34) yielded an unprocessed precursor as well as two pro-
and the mutant peptide (I25 r A and I29 r A) were sepa- cessed products with apparent molecular mass of 36,
rately mixed with the NS3 fusion protein. The mixture 29, and 7 kDa, respectively (Fig. 2, lanes 2 and 3). Pro-
was incubated with the Ni-NTA beads (histidine binding cessing was clearly evident by NS3 with or without NS4A;
resin; Qiagen, Inc.) in a final buffer concentration of 40 however, efficiency of the cleavage was improved in the
mM sodium phosphate, pH 7.8, 0.2 M NaCl, 8 mM b- presence of the NS4A peptide (compare lanes 3 and 2).
mercaptoethanol, 0.2% Tween 20, and 20% glycerol, at a From estimating the relative sizes of cleavage products
proteinase to peptide molar ratio of 1:2.5. Bead-bound we identified the larger product as D4B and the smaller
complexes were separated by centrifugation (12,000 rpm as either DNS3/4A or 4A, indicating cleavage at 4A/4B
for 30 sec in a microcentrifuge), washed with wash buffer site. The cleavage at the 3/4A junction of the precursor
(50 mM sodium phosphate, pH 7.8, 0.3 M NaCl, 10 mM protein was difficult to observe since the processed
b-mercaptoethanol, 0.1% Tween 20, and 25% glycerol) to DNS3 product with a predicted molecular mass 0.8 kDa
remove free peptides, and assayed for the cleavage of was too small to be detected in this assay. As expected,
DNS4A-D4B substrate. Imidazole was added (final conc processing was not observed in the absence of NS3
150 mM ) to a duplicate set of reaction samples to elute (lane 1). Minor bands observed in this autoradiogram are
the histidine-tagged complex from the beads. Similarly, possibly due to incomplete synthesis of the full length
an additional control experiment was set up by incubat- substrate during in vitro translation. As in NS4A/4B, the
ing the 13-amino-acid peptide alone with the beads. The processing of the precursor polypeptide containing the
complex was then washed as previously described and 5A/5B site by the NS3 alone was observed (Fig. 2, lane
assayed for activity in the presence of NS3 proteinase. 8), and was much improved in the presence of the NS4A
peptide (compare lanes 9 and 8). The two products of
RESULTS predicted molecular mass of 22.4 and 12 kDa correspond
to the D5B and D5A proteins, respectively. The bandCofactor activity of NS4A in NS3-mediated
representing the cleavage product DNS5A producedproteolysis
from DNS5A-DNS5B protein (lanes 8 and 9) was consis-
tently observed to migrate slower than its expected mo-To study the role of NS4A on the NS3-mediated trans-
cleavages at NS4A/4B, 4B/5A, and 5A/5B of HCV non- lecular mass. High proline content in DNS5A (16%)
and the precursor protein DNS5A-DNS5B possibly affectstructural polyprotein, a series of HCV polypeptides with
specific cleavage site(s) were produced by a cell-free the mobility in gel electrophoresis (Zakut-Houri et al.,
1983). We did not observe any detectable cleavage attranscription–translation system and processed in a
trans-cleavage reaction by NS3 proteinase with or with- the 4B/5A site of the precursor polypeptide (D4B/D5A)
by NS3 alone (Fig. 2, lane 5). However, the polypeptideout NS4A. Figure 1 shows a schematic representation of
polyprotein substrates. The NS3 proteinase used in this was cleaved to the expected products D4B and D5A
when NS4A peptide was included in the cleavage reac-study is described under Materials and Methods. For
NS4A we began with the carboxyl-end 33-amino-acid tion (Fig. 2, lane 6).
These results indicate that while the NS3 proteinasepeptide (aa 22–54 of NS4A) of the HCV-1b (BK) strain
(Failla et al., 1994). The in vitro-translated polypeptide alone is sufficient for the cleavage at 4A/4B and 5A/5B
sites, addition of NS4A is required for the cleavage atsubstrates were incubated with the NS3 proteinase in the
AID VY 8232 / 6a23$$$142 10-16-96 03:54:06 vira AP: Virology
331HCV NS3 PROTEINASE NS4A COFACTOR INTERACTION
FIG. 2. HCV NS3 proteinase activity //0 4A peptide on HCV polyprotein cleavage sites. 35S-labeled substrates DNS3-4A-D4B (lanes 1–3), D4B-
D5A (lanes 4–6), and D5A-D5B (lanes 7–9) were produced by in vitro translation in rabbit reticulocyte lysates as described under Materials and
Methods. Labeled substrates and 1 mM purified NS3 proteinase were incubated in the presence or absence of 2 mM NS4A synthetic peptide [aa
22–54, HCV-1b (BK) strain] for 1 hr at 307. The samples were analyzed on SDS–15% PAGE. HCV proteins are indicated by arrows. Molecular weight
markers in kDa are shown on the left.
4B/5A site; NS4A increases the cleavage efficiency at (FDA) strain was less active in our assay than its counter-
part from the 1b (BK) strain (compare lanes 8 and 9, Fig.4A/4B and 5A/5B junctions. This is consistent with the
results reported using transient expression of the HCV 4A). On peptide analysis (data not shown) we found that
the cysteine content in the FDA peptide was rapidly de-polyprotein in whole cells (Failla et al., 1994, 1995; Lin
et al., 1994). The ability of the 33-aa peptide (aa 22–54) creased with time in DMSO, whereas the tyrosine con-
tent was unchanged, suggesting that the 2 terminal cys-derived from NS4A sequence in HCV-1b (BK) to act as a
cofactor for HCV-1a (FDA) NS3 proteinase indicates teine residues in the FDA peptide were oxidized to a
less active form.cross-reactivity between the two subtypes.
The central 18-aa peptide (aa 19–36) which appears
to be sufficient for the NS4A cofactor activity in our bio-Mapping the minimum domain of NS4A for cofactor
chemical assays was progressively truncated at both ter-activity
mini to determine the minimum region necessary for the
The results described above clearly suggest that the NS4A cofactor activity. The various truncated forms were
carboxy-terminal 33-aa peptide of NS4A is a cofactor for assessed for activity in the in vitro proteinase assay. The
the NS3-catalyzed cleavages in the nonstructural region results are shown in Fig. 4B. We found that truncation of
of HCV polyprotein. To further characterize NS4A cofac- the 18-aa peptide (aa 19–36) to a 14-aa peptide (aa 21–
tor activity, additional truncations were made in the NS4A 34) and subsequently to a 13-mer (aa 22–34) did not
sequence of HCV-1a (FDA), as shown in Fig. 3. The trun- significantly affect the cofactor activity in our assay (Fig.
cated peptides were evaluated for their activity in a trans- 4B, lanes 5 and 7). However, further deletion of the
cleavage reaction using the 5A/5B polypeptide substrate. amino-terminal cysteine residues from the 13-mer (aa
We observed that in addition to the HCV-1b (BK) strain 22–34) peptide resulted in a loss of the activity (lane
C-terminal 33-aa peptide, the HCV-1a (FDA) strain car- 10), implying that the cysteine residue is important for
boxy-end 33-aa peptide (aa 22–54) and an 18-aa peptide cofactor activity, and hence delineating the amino-termi-
(aa 19–36) were able to enhance the NS3 proteinase nal boundary of the domain. For the carboxy-end bound-
activity (Fig. 4A, lanes 8, 9, and 10). In contrast, other ary, we found that the cofactor activity was retained until
NS4A peptides, including the amino-terminal 21-aa (aa removal of the glycine residue (G33) from the 13-mer (aa
1–21) and two shorter truncations from the carboxyl end, 22–34) peptide; this removal abolished the cofactor-en-
a 15-mer (40–54 aa) and a 22-mer (aa 33–54), were hanced cleavage activity within the limits of detection in
found to have no detectable enhancement activity in this our assay (compare lane 9 to lane 2). These results sug-
assay (lanes 5, 6, and 7, respectively). A non-HCV peptide gest that the 12-aa residue (aa 22 to 33) of NS4A consti-
of 18-aa was also found to be inactive (Fig. 4A, lane 4). tutes the core sequence necessary to enhance the NS3-
catalyzed proteolysis. Similarly, a 12-aa peptide (aa 22–The C-terminal 33-aa peptide (aa 22–54) from the 1a
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FIG. 3. Sequence of NS4A peptides used in these studies. Sequence of the complete NS4A protein is shown in the box, with the minimum
sequence for cofactor activity underlined. The 4A peptides shown above the box had no activity; those peptides shown below the box retained
cofactor activity. Dashed lines in BK-specific sequences represent identical amino acids within the FDA strain while the letters designate differences
in the sequences.
33) containing the NS4A from HCV-1b (BK) was found demonstrate that NS4A cofactor activity is required for
cleavage at the 4A/4B site by NS3 proteinase.to be the minimum domain needed to enhance NS3-
mediated proteolysis. The same minimum sequence is
sufficient for the NS3-mediated cleavage at 4B/5A site Identification of important residues in the NS4A
(N. J. Butkiewicz, unpublished data). peptide for cofactor activity
The ability of the 12-aa NS4A (aa 22–33) peptide toRequirement of NS4A for cleavage at the
act as a cofactor in the NS3-mediated proteolysisNS4A/4B site
prompted us to further characterize the underlying inter-
action by studying the importance of individual aminoThe polypeptide substrate with the NS4A/4B site
was observed to be cleaved by NS3 alone (Fig. 2, lane acids in the cofactor activity. We synthesized a series of
NS4A peptide derivatives by sequentially substituting an2). This is possibly due to the fact that the NS4A cofac-
tor sequence is present as a part of the polypeptide alanine residue for each amino acid in the 13-mer pep-
tide (aa 22–34) containing the NS4A 1a (FDA) sequencesubstrate. NS4A has been shown to activate the NS3
proteinase when fused to the substrate (Failla et al., (Fig. 6A). The alanine-substituted peptides were evalu-
ated for cofactor activity in trans-cleavage reactions us-1994) or coproduced with enzyme (Lin and Rice, 1995).
Having identified the minimum domain of NS4A for the ing NS3 proteinase and polypeptide substrates DNS4A-
D4B and DNS5A-D5B. The mutated peptides werecofactor activity, we examined its role on the NS3-
mediated cleavage at the NS4A/4B site by deleting the tested at comparable concentrations (1.5 mM ) as deter-
mined by amino acid analysis. Results are summarizedcofactor sequence from the polypeptide substrate. The
modified DNS4A-DNS4B substrate (25.4 kDa) con- in Figs. 6B and 6C. We found that the substitution of
alanine for isoleucine 29 abolished the cleavage at bothtaining amino acid residues from 36 through 54 of
NS4A and the amino-terminal 192 aa of NS4B was the 4A/4B and the 5A/5B sites within the limits of detec-
tion (lane 11, Figs. 6B and 6C); the cofactor activity wasexpressed in a cell-free translation system and pro-
cessed with NS3 proteinase with and without the addi- not recovered even using the peptide at five times higher
concentration (data not shown). In addition to the substi-tion of the NS4A peptide. In the absence of the NS4A
cofactor sequence, the modified NS4A-4B substrate tution at I29, we observed that the substitution of alanine
for the amino acids V24, I25, and V26 caused a significantwas not cleaved by the NS3 proteinase (Fig. 5, lane 2);
however, the substrate was readily cleaved when the reduction of the NS4A cofactor activity as shown by de-
creased product formation (lanes 6, 7, and 8, respec-14-aa NS4A (aa 21 – 34) peptide was included in the
reaction mixture (Fig. 5, lane 3). These results clearly tively, Figs. 6B and 6C). Substitution with an alanine resi-
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central region of NS4A, especially I29, play critical roles
in NS4A-mediated cofactor activity.
Complex formation between NS3 and the NS4A
peptide and demonstration of the activity
Finally, we examined whether the peptide can form an
enzymatically active complex with the proteinase. Taking
advantage of the polyhistidine tag in the His-HIV-NS3
183 fusion protein, we used Ni-NTA beads to isolate the
NS4A peptide–enzyme complex from free peptides. The
complex was assayed in the 4A-dependent cleavage re-
action using the DNS4A-D4B polypeptide substrate to
show the presence of the NS4A. A 13-aa residue peptide
(aa 22–34) and the mutant peptide with I25A and I29A
substitutions were used in the experiment. Results are
shown in Fig. 7A. Processing of the polypeptide substrate
was observed by the imidazole-treated beads containing
the native peptide and the enzyme (Fig. 7A, lane 5); cleav-
age activity was also observed, to a lesser extent, in the
complex without imidazole elution (Fig. 7A, lane 2). None
of the other bead preparations which were incubated
with the NS3 alone (lanes 1 and 4) or with the mixture
of NS3 and the mutated peptide (lanes 3 and 6) showed
any proteinase activity. The results suggest that the 13-
aa residue NS4A peptide interacts, possibly via specific
hydrophobic residues, with the NS3 catalytic domain to
form an enzymatically active complex. This is further sup-
ported by the fact that nonspecific association of the
peptide with beads, if any, did not contribute toward co-
FIG. 4. Mapping the minimal NS4A domain required for enhancement
of NS3 proteinase activity. 35S-labeled DNS5A-D5B substrate was incu-
bated with 1 mM purified NS3 proteinase in the presence of synthetic
peptides from various NS4A sequences. HCV proteins are shown on
the right; molecular weight markers in kDa are on the left. Unless
indicated as BK (strain), all NS4A sequence is from HCV-1a (FDA)
strain. (A) NS4A peptides were tested at 1 mM. A non-HCV NS4A 18-aa
peptide (SNAEAGALVNASSAAHVD) was also tested. (B) NS4A peptides
were tested at 2 mM.
due at amino acids V23, G27, V30, and L31 was also found
to impair the cofactor activity in our assay, particularly
FIG. 5. Absolute requirement for NS4A in DNS4A-D4B cleavage.for NS5A/5B cleavage reaction (Fig. 6C, lanes 9, 12, and
35S-labeled substrate DNS4A-D4B (aa 1693–1903), which does not13). Substitution outside the minimum domain (K34A)
contain the minimum cofactor domain of NS4A, was incubated with
was observed to have marginal effect on cleavage at 5A/ NS3 proteinase plus or minus 2 mM NS4A synthetic peptide (aa 21–
5B site only (Fig. 6C, lane 16). These results strongly 34). HCV proteins are shown on the right; molecular markers in kDa
are on the left.suggest that the hydrophobic amino acid residues in the
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FIG. 6. Cofactor activity of alanine-substituted peptides derived from the 13-mer peptide (aa 22–34) of NS4A. (A) Wild-type (WT) alanine-substituted
4A peptides used in this study. Cofactor activity was tested at 1.5 mM on two substrates: DNS4A-D4B (B) and DNS5A-D5B (C). The alanine-
substituted residue and the corresponding amino acid number in NS4A are shown above each lane. HCV proteins are shown on the right; molecular
weight markers in kDa are on the left.
factor activity (Fig. 7B, lane 3). The cofactor activity of the study the role of NS4A in NS3-catalyzed proteolysis of
HCV nonstructural proteins in a cell-free biochemicalNS4A peptide was only observed when the peptide was
incubated with beads in the presence of NS3 (Fig. 7B, assay. We show that the central hydrophobic region of
NS4A (aa 22 – 33) is sufficient to act as a cofactor forlane 2). As expected, the bead preparation without NS4A
peptide did not show any protease activity (Fig. 7B, lane NS3-mediated proteolysis at 4A/4B, 4B/5A, and 5A/5B
sites. Previous studies using cell-free translation and1). These results clearly suggest that NS4A peptide spe-
cifically interacts with NS3 to form an enzymatically ac- cell culture transient expression of HCV polyprotein
proposed a similar minimum functional domain fortive complex.
NS4A (Lin et al., 1995; Bartenschlager et al., 1995; Tanji
DISCUSSION et al., 1995).
Since NS4A has been shown to enhance NS3 activityIn this report, we have used the purified NS3 protein-
ase catalytic domain and NS4A synthetic peptides to in cis, when fused with the substrate, or in trans (Failla
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FIG. 7. Complex formation of NS3 proteinase with NS4A peptide. (A) Purified NS3 proteinase and NS4A synthetic peptide (aa 22–34), either
native or double mutation (I25A, I29A), were allowed to interact together with Ni-NTA beads at 47 for 1 hr. Washed beads were tested for active
complex formation by in vitro translation assay using DNS4A-D4B substrate, in the presence or absence of 150 mM imidazole. (B) An additional
complex consisting of NS4A peptide (aa 22–34) and Ni-NTA beads was tested as control. Just before assay, 0.1 mM NS3 proteinase and 150 mM
imidazole were added to the reactions.
et al., 1994; Bartenschlager et al., 1994), the presence of (1995) in cell culture protein processing studies. Ala-
nine substitution of other hydrophobic amino acids inthe minimum functional region of NS4A sequence in 4A-
4B polypeptide substrates warranted further character- the peptide (V24, I25, V26, V30, and L31) inhibited the cofac-
tor activity, whereas little or no effect was observedization. By deleting the minimum functional sequence
from the NS4A-4B polypeptide substrate, we have dem- for C22 or R28. Interestingly, deletion of either C22 in
HCV-1a (FDA) or S22 in HCV-1b (BK) abolished cofactoronstrated that, like the proteolytic processing at 4B/5A
junction (Fig. 2), the cleavage at the 4A/4B site requires activity of the peptides (Fig. 4B), indicating that an
amino acid residue at this position may have a role inthe NS4A cofactor activity (Fig. 5). The requirement of
the same functional domain of NS4A for all these trans- structural stabilization. From secondary structure pre-
dictions, this central region of NS4A exhibited a highprocessing activities of NS3 indicates a common mecha-
nism for NS4A even though the stringency of its func- propensity for the formation of a b-strand-like struc-
ture. Compatible with this prediction, it has been dem-tional requirements are different.
The significance of the NS4A central domain, partic- onstrated from CD analysis that a synthetic peptide
containing amino acid residues 22 to 33 of NS4Aularly the hydrophobic amino acids, in NS3-mediated
cleavages of HCV polyprotein has been reported in adopts a b-strand conformation in solution (W. Wind-
sor, personal communication). It is possible that theprevious studies (Lin et al., 1995; Bartenschlager et
al., 1995). Our experiments, which focused on further local conformation of this region of NS4A is b-strand-
like, and upon complex formation with the NS3 protein-characterization of the peptide sequence in respect
to the individual amino acid residues required for the ase domain, favorable interactions are elicited, mainly
through hydrophobic contacts from residues involvingcofactor activity, have identified isoleucine residue (I29)
as a critical amino acid for the 4A-dependent and 4A- V24, I25, V26, V30, and L31, and in particular I29. Primary
sequence analysis of different HCV strains corre-augmented NS3 proteinase activity (Figs. 6B and 6C).
This amino acid residue is also important for cofactor sponding to this central region of NS4A indicates that
amino acid residues at positions I25, V26, and I29 areactivity in processing at the 4B/5A junction, since its
substitution to alanine abolished the cofactor activity highly conserved, allowing for only very conservative
substitutions to occur (e.g., V26I, I29V, L). In contrast,of the peptide (N. J. Butkiewicz, unpublished results).
The importance of I29 for the cofactor activity of full the substitution pattern of residues at positions 30 to
33 are much more diverse, with a high degree of toler-length NS4A has been demonstrated by Lin et al.
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ance for nonconservative substitutions in some cases containing sequence of HCV-1a (FDA) (Fig. 4B, lanes
5 and 4), and among the 13-mer (aa 22 – 34) and the(e.g., V30H, E; S32N, E; G33Q, D). It should be noted
that the 12-amino-acid residue peptide, aa 22 – 34 from 33-mer (aa 22 – 54) of HCV-1b (BK) peptides (Fig. 4,
lanes 6 and 3). This is in agreement with the reportedHCV-NZL1 strain (CVVIVGHIEIEGK), was found to en-
hance the cleavage at 5A/5B junction in our assay (But- data (Steinkuhler et al., 1996), where two peptides
(Pep4a21-34 and Pep4A21-54) were indistinguishablekiewicz et al., unpublished results). While this manu-
script was being prepared, Shimuzu et al. (1996), using in activating NS3. These results indicate that the mini-
mal activating sequence of NS4A is sufficient for inter-various substitutions in the NS4A peptide, observed
that amino acid residues V23, I25, G27, R28, I29, and L31 action with NS3, although full length NS4A, which is
involved in multiple interactions with NS3, is possiblywere important for enhancing the cleavage of NS 5A-
5B synthetic peptide substrate by the full length NS3 required for stabilizing the complex and/or for mem-
brane association.proteinase. Except for R28, the findings are in agree-
ment with our observations. Interestingly, the observa- Specific proteolysis to produce mature viral products
is critical for replication of many viruses, and regula-tion that substitution of the arginine residue with a
serine residue is less deleterious for cofactor function tion of these specific events to prevent inappropriate
proteolysis is obviously vital. Viruses employ variousthan with either aspartic acid or glutamine (Shimuzu
et al., 1996) suggests that a neutral or weakly hy- mechanisms to modulate this important function. In
HIV-1, dimerization is required for activation of the pro-drophobic amino acid is better tolerated in that posi-
tion. This is supported by our findings that R28A substi- teinase (Navia et al., 1989); also, Krausslich et al.
(1991) showed that premature activation of the HIV-1tution did not significantly affect the cofactor activity.
The mechanism by which NS4A activates NS3-medi- protease is toxic to cells and prevents virus assembly.
Ribosomal frameshifting to produce gag – pol fusionated proteolysis of HCV nonstructural protein is not
clear. NS4A is cleaved off from the proteinase by an protein containing the protease is possibly used to
limit the amount of protease synthesis (Jacks et al.,intramolecular cleavage and has been shown to acti-
vate the proteinase in cis or in trans (Failla et al., 1994; 1988). In adenovirus, a heterodimeric complex forma-
tion between an 11-amino-acid residue virus-encodedLin et al., 1994). Liberation of NS4A from polypeptide
substrates is not a prerequisite for its activity (Failla peptide and the protease is required for enzyme activa-
tion (Webster et al., 1993; Mangel et al., 1993). Foret al., 1994). NS4A can activate NS3 proteinase even
when it is covalently fused to the proteinase domain picornaviruses, the proteolytic cleavages within the
capsid precursor P1 are catalyzed by a complex con-(Hahm et al., 1995; Butkiewicz and DasMahapatra, un-
published results). It has been suggested that, like the taining the 3C proteinase and 3D polymerase (Ypma-
Wong et al., 1988; Jore et al., 1988). It is noted thatNS2B/3 proteinase in flaviviruses (Arias et al., 1993;
Chambers et al., 1991; Falgout et al., 1993), NS4A-as- several other viral proteases, including flavivirus NS3
(Rice, 1995) and Sindbis virus nsp2 (de Groot et al.,sisted cleavage reactions in HCV are carried out by
a proteinase complex consisting of NS3 and NS4A. 1990), require a cofactor to catalyze proteolysis. It is
possible that HCV may adopt a similar strategy to coor-Although the full length NS4A has not been used in our
binding experiments, the ability of the 13-aa cofactor dinate the regulation of its nonstructural protein pro-
cessing to mature products by modulating the NS3peptide to form an enzymatically active complex with
the proteinase domain suggests that active proteinase proteinase activity. Understanding the nature of the
interaction between the NS3 proteinase and the NS4Ais a heterodimeric complex between NS3 and NS4A.
Complex formation between NS3 and NS4A has been cofactor will provide an attractive alternative target for
the development of specific proteinase inhibitors assuggested based on their ability to form an immuno-
precipitable complex in transfected cells (Lin et al., clinically viable antiviral agents.
1995; Bartenschlager et al., 1995). Based on coimmu-
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